Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Participant must be 18 years of age or older.~2. Participant must understand and sign the protocol's informed consent document.~3. Participant is willing to comply with the study procedures and return for all study visits.~4. Participant has chronic macular edema secondary to non-infectious panuveitis, posterior or intermediate uveitis in at least one eye (the study eye) that has:~   1. not been responsive to conventional immunosuppressive therapy in the past 3 months; OR~  2. recurred while on conventional immunosuppressive therapy.~5. Participant has central macular thickness of ≥ 270 microns in the study eye.~6. Participant has visual acuity of 20/400 or better (≥ 19 ETDRS letters) in the study eye.~7. Female participants of childbearing potential must not be pregnant or breast-feeding, must have a negative serum pregnancy test at screening and must be willing to undergo serum pregnancy tests throughout the study.~8. Both female participants of childbearing potential (see Appendix 1 for definition) and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two acceptable methods of contraception throughout the course of the study and for six months after the last study medication injection. Acceptable methods of contraception include:~   * hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring),~  * intrauterine device,~  * barrier methods (diaphragm, condom) with spermicide, or~  * surgical sterilization (tubal ligation).~EXCLUSION CRITERIA:~1. Participant is in another investigational study and actively receiving investigational therapy for macular edema.~2. Participant has evidence of infectious panuveitis, posterior or intermediate uveitis in either eye.~3. Participant is expected to need ocular surgery in the study eye during the course of the trial.~4. Participant had intraocular surgery in the study eye within the past 90 days.~5. Participant had an injection of bevacizumab or ranibizumab within the past four weeks in the study eye.~6. Participant had an injection of triamcinolone within the past six weeks in the study eye.~7. Participant has a systemic condition that, in the opinion of the investigator, would preclude participation in the study.~8. Participant has significant cataract or media opacity in the study eye that makes posterior segment visualization difficult as determined by investigator.~9. Participant has a confirmed positive serologic and/or molecular test for HIV-1/2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: EXPERIMENTAL): 400 μg/100 μL injection

Based on this trial design, predict the completion outcome and termination type (if applicable).